Sanofi-Aventis Articles
Regeneron/Sanofi colorectal cancer drug Zaltrap will see peak-year sales of up to $250 million
13 May 2011
Sanofi-Aventis net profit in 1st-qrt 2011 slumps 29%, battered by generics and low flu sales
29 April 2011
Sanofi-Aventis collaborates with Stanford University Bio-X on early-stage scientific research
19 April 2011
New president and CEO at Astellas Pharma Europe and in USA; Ex-Genzyme CEO joins AVEO board
13 April 2011
Sanofi-Aventis to expand insulin capacity in Russia
29 March 2011
Merck & Co and Sanofi-Aventis drop plans to merge animal health operations; latter prices bond issue
23 March 2011
Lilly names former Genentech exec as VP oncology research; Sanofi-Aventis names SDSAC chairman
11 March 2011
Strong Ph II data for Genzyme’s second Gaucher drug eliglustat
21 February 2011
Agreement on Sanofi-Aventis/Genzyme deal prompts lawyer comment on Europe/USA differences on takeovers
17 February 2011
Genzyme finally agrees takeover deal, as Sanofi-Aventis ups its offer to $74/share plus CVR
16 February 2011
Sanofi-Aventis in deal with Sunnybrook Health to develop treatment for diabetic foot ulcers; viewing ophthalmic acquisitions
16 February 2011
Diabetes pipeline cannot reverse cardiovascular and metabolic market decline, says Datamonitor
10 February 2011
Sanofi-Aventis net 4th-qtr 2010 falls, but still beats forecasts, as Genzyme talks progress
9 February 2011
Progress in Sanofi-Aventis bid to acquire Genzyme as it is allowed to conduct due diligence
1 February 2011
Disappointments as Actelion and GSK discontinue almorexant in sleep disorder and Sanofi’s iniparib fails in Ph III
28 January 2011
US FDA grants pediatric exclusivity for Sanofi/B-MS Plavix; rejects Gilead’s filing for combination AIDS pill
26 January 2011
US FDA issues action letter for Teva’s generic Lovenox; grants orphan status for BioSante vaccine
26 January 2011
Sanofi-Aventis in-licenses Oxford BioTherapeutics antibody for the treatment of solid cancers
25 January 2011
Novartis to acquire companion diagnostics maker Genoptix for around $470: Sanofi extends Genzyme offer
24 January 2011
EMA advisory committee backs Gilenya, Halaven, Jevtana, Pravafenix and Trobalt, but negatives for Fampyra and Multaq
24 January 2011
European Commission launches second monitoring purge of patent settlements in pharma sector
18 January 2011
US FDA warns on acute liver failure with Sanofi-Aventis Multaq
17 January 2011
Sanofi-Aventis gets EC approval for Genzyme bid; links with UCSF for early-stage research
13 January 2011
Genzyme posts record 4th-qtr 2010 revenues but cuts 2011 guidance, as Sanofi-Aventis talks continue
12 January 2011
Sanofi-Aventis confirms it is considering CVR-based deal regarding takeover of Genzyme
10 January 2011
USA’s FDA puts stops on Johnson & Johnson’s fulranumab and Regeneron/Sanofi-Aventis osteo drug due to side effect risks
4 January 2011
Genzyme touts value of alemtuzumab for MS in bid to get Sanofi to raise its hostile offer
21 December 2010
Sanofi-Aventis in $800 million deal with Avila; links up with Merck KGaA and with Oxford University for cancer research
20 December 2010
Another exec change at Sanofi-Aventis, as it appoints R&D chief
15 December 2010
Merck KGaA replaces Schnee; Sanofi-Aventis makes senior executive change and extends Genzyme tender offer
13 December 2010
Momenta Pharma sues Teva for enoxaparin patent infringement
3 December 2010
Genzyme meets first milestones of FDA consent decree
25 November 2010
Genzyme hives off Diagnostics business to Japan’s Sekisui Chemical for $265 million; “white knight” expectations not certain
19 November 2010
US FDA to fast-track Sanofi Pasteur's investigational Clostridium difficile vaccine
11 November 2010
Sanofi-Aventis tells takeover target Genzyme to clarify potential board actions; Genzyme sticks to its guns on value
9 November 2010
UK families denied legal aid for epilepsy drug sodium valproate court case against Sanofi-Aventis
8 November 2010
Sanofi-Aventis finds no reason to raise bid for Genzyme
28 October 2010
Despite economic crisis, top EU firms cut R&D investment less than US rivals, but Europe still behind; strong pharma showing
27 October 2010
Positive vaccine trial results from Novartis, Sanofi Pasteur and LigoCyte presented at IDSA meeting
26 October 2010
Genzyme argues case for higher valuation than Sanofi-Aventis ‘hostile offer, saying it is worth $89 a share
25 October 2010
Sanofi-Aventis collaborates with Harvard University on translational biomedical research
19 October 2010
Positive Ph II five-year results with Genzyme’s alemtuzumab in MS patients could prompt higher bid from Sanofi, observers suggest
18 October 2010
Sanofi-Aventis’ oral drug teriflunomide reduces relapses in multiple sclerosis patients by 31%
18 October 2010
USA’s FDA calls for label changes on bisphosphonates due to possible increased risk of thigh bone fracture
14 October 2010
Strong cancer drug results presented by Roche, Sanofi-Aventis, Merck KGaA, Amgen and Eisai at ESMO Congress
12 October 2010
Sanofi-Aventis to cut 25% of workforce in US pharmaceutical operations as it faces a slew of patent expiries; signs vaccine preparedness deal
11 October 2010
Genzyme board unanimously rejects Sanofi-Aventis’ $69/share tender offer as “inadequate and opportunistic”
8 October 2010
Sanofi-Aventis goes hostile with $69/share offer for Genzyme
4 October 2010
Sanofi-Aventis presents strong date for once-daily lixisenatide in combination with basal insulin; settles with Proteome
1 October 2010
Covance enters $2.2 bn R&D alliance with Sanofi-Aventis
30 September 2010
Sanofi facing generic Taxotere competition in USA; first biosimilar cleared in Australia
30 September 2010
Bisphosphonates under scrutiny in Europe over link to stress fractures
28 September 2010
Sanofi may up bid for Genzyme, buys VaxDesign for $60m
28 September 2010
Sanofi-Aventis’ riferminogen pecaplasmid fails Ph III endpoints; partner Vical’s shares decimated; provides opportunity for Aastrom?
23 September 2010
Positive new data on diabetes drugs from Novo Nordisk, AstraZeneca/B-MS and Sanofi-Aventis presented at EASD meeting
21 September 2010
Sanofi-Aventis CEO reasonably confident of doing deal for Genzyme, but in no hurry
16 September 2010
Genzyme snubs Sanofi-Aventis’ $18.5 billion offer; French drugmaker reports good data for MS drug teriflunomide
31 August 2010
Highlights of ESC include strong data on AstraZeneca’s Brilinta and Servier’s Procoralan; ESC guideline for atrial fibrillation
31 August 2010
Sanofi-Aventis breaks silence on Genzyme acquisition, offering $18.5 billion for the troubled US biotech firm
30 August 2010
Regulatory briefs: Shire’s Vpriv cleared in Europe; Menactra for toddlers; Updates for Novartis and Roche
27 August 2010
Draft guidance from UK’s NICE recommends Celgene and Janssen Cilag multiple myeloma drugs; Sanofi-Aventis’ Multaq approved for AF
27 August 2010
26 August 2010
Human Genome Sciences lures Celgene exec to help in European launch of Benlysta; Sanofi-Aventis announces executive moves in Asia
15 August 2010
Sanofi-Aventis signs personalized medicine deal with Scripps; foray into generics sector assessed
11 August 2010
UK’s NICE issues guidance on blood clotting drugs Plavix and Persantin/Asasantin; PMCPA consults on ABPI Code of Practice
6 August 2010
Sanofi-Aventis 2nd-qtr 2010 earnings up 8%, but firm still mute on Genzyme acquisition; sues over Lovenox
29 July 2010
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
